EFFICACY OF IXEKIZUMAB IMPROVING SF-36 SCORES IN BIOLOGIC DMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)

被引：0
|
作者：
Strand, V. [1 ]
Gottlieb, A. B. [2 ]
Kvien, T. K. [3 ]
Naegeli, A. [4 ]
Lin, C-Y. [4 ]
Benichou, O. [4 ]
Birt, J. [4 ]
机构：
[1] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[2] New York Med Coll, Valhalla, NY 10595 USA
[3] Diakonhjemmet Hosp, Oslo, Norway
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.2331
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0793
引用
收藏
页码：1334 / 1335
页数：2
相关论文
共 50 条
  • [41] AN ANALYSIS OF FATIGUE IN PATIENTS WITH PSORIATIC DISEASE UTILIZING SF-36 VITALITY SCORES: RESULTS THROUGH WEEK 24 IN PHASE 3 TRIALS OF GUSELKUMAB IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS
    Merola, J. F.
    Liu, Y. H.
    Yang, Y. W.
    Miller, M.
    Shawi, M.
    Chan, D.
    Khattri, S.
    Savage, L.
    Boehncke, W. H.
    Han, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1573 - 1574
  • [42] Effect of concomitant conventional disease-modifying antirheumatic drug (cDMARDS) on safety and efficacy of ixekizumab in biologic dmard (bDMARD) naive patients with active psoriatic arthritis (PsA)
    Coates, L. C.
    Gottlieb, A. B.
    Shuler, C. L.
    Lin, C. -Y.
    Samanta, S.
    Moriarty, S. R.
    Lee, C. H.
    Mease, P. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 32 - 32
  • [43] Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
    Mease, Philip J.
    van der Heijde, Desiree
    Ritchlin, Christopher T.
    Okada, Masato
    Cuchacovich, Raquel S.
    Shuler, Catherine L.
    Lin, Chen-Yen
    Braun, Daniel K.
    Lee, Chin H.
    Gladman, Dafna D.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) : 79 - 87
  • [44] EFFICACY AND SAFETY OF IXEKIZLTMAB VERSUS ADALIMUMAB (SPIRIT-H2H) WITH AND WITHOLIT CONCOMITANT CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIMIEUMATIC DRUGS (DMARD) IN BIOLOGIC DMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 52-WEEK RESULTS
    Smolen, Josef S.
    Sebba, Anthony
    Ruderman, Eric M.
    Gellett, Amanda M.
    Sapin, Christophe
    Sprabery, Aubrey Trevelin
    Liu-Leage, Soyi
    Pillai, Sreekumar
    Reis, Patilo
    Nash, Peter
    Tostes, Camila de Lima
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S137 - S137
  • [45] Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naive or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
    Husni, M. Elaine
    Mease, Philip J.
    Merola, Joseph
    Behrens, Frank
    Favalli, Ennio Giulio
    McGonagle, Dennis
    Tillett, William
    Tsuji, Shigeyoshi
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Lambert, Jeremy
    Gossec, Laure
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4197 - 4199
  • [46] Certolizumab Pegol in Combination with Methotrexate in DMARD-Naive Patients with Active, Severe, Progressive Rheumatoid Arthritis: Results from a Randomized, Double-Blind, Controlled Phase 3 Study
    Weinblatt, Michael
    Bingham, Clifton
    Burmester, Gerd
    Bykerk, V. P.
    Furst, Daniel E.
    Mariette, Xavier
    van der Heijde, Desiree
    Tatla, Daljit
    Arendt, Catherine
    Mountian, Irina
    VanLunen, Brenda
    Emery, Paul
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [47] Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1) (vol 10, pg 1683, 2023)
    Kameda, Hideto
    Hagimori, Kohei
    Morisaki, Yoji
    Holzkamper, Thorsten
    Konomi, Ayako
    Dobashi, Hiroaki
    RHEUMATOLOGY AND THERAPY, 2024, 11 (04) : 1057 - 1057
  • [48] BIMEKIZUMAB TREATMENT RESULTED IN IMPROVEMENTS IN FATIGUE AND PAIN IN BIOLOGIC DMARD-NAIVE OR TNFI-IR PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED 16-WEEK RESULTS FROM TWO PHASE 3 RANDOMISED, PLACEBO-CONTROLLED STUDIES
    Rischmueller, Maureen
    Husni, M. Elaine
    Mease, Philip J.
    Merola, Joseph F.
    Behrens, Frank
    Favalli, Ennio G.
    McGonagle, Dennis
    Tillett, William
    Tsuji, Shigeyoshi
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Lambert, Jeremy
    Gossec, Laure
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 26 - 26
  • [49] Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study
    Gratacos, Jordi
    Turkiewicz, Anthony
    Dokoupilova, Eva
    Gellett, Amanda
    Sprabery, Aubrey
    Geneus, Vladimir
    Constantin, Arnaud
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [50] Efficacy of ixekizumab in patients with psoriatic arthritis: Results of a phase 3 randomized, double-blind, active- and placebo-controlled study
    Mease, Philip
    van der Heijde, Desiree
    Ritchlin, Christopher
    Cuchacovich, Rachel
    Shuler, Catherine
    Lin, Chen-Yen
    Vangerow, Harald
    Samanta, Suvajit
    Lee, Chin
    Gladman, Dafna
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
12345